Navigation Links
Bayer Introduces Fitness Program for Children and Young Adults with Hemophilia A
Date:10/26/2010

age members of the hemophilia community to embrace fitness.  The symposium will feature the Season 5 at-home winner from NBC's "The Biggest Loser®," Bernie Salazar, and nutrition expert Rebecca Scritchfield, RD, who will be there to help motivate attendees.

Living Fit! also offers FactorTrack™, the first free, personal and interactive mobile application that helps make it easier to track and record factor infusions.  Living Fit! also includes downloadable fitness guidelines, designed by a team of physical therapists who work with people with hemophilia A.  FactorTrack and the guidelines are available at www.livingwithhemophilia.com/webapp/livingfit.  In addition, a Living Fit! Patient Kit, including educational materials and a DVD with demonstrations of the program's components, are available through Bayer Hemophilia Account Executives.

For more information about Living Fit!, please visit www.livingwithhemophilia.com/webapp/livingfit.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcar
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and administration of cell therapies, today said that it ... Platform (AXP) used for the processing of cord blood. ... in the country later this year. "We ...
... Mass., May 22, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, announced today that it has received ... serving the muscular dystrophy patient community. Halo will ... study of HT-100, its lead drug candidate for ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... 2014 CBPartners, a global leader in ... a new website. The redesigned site boasts improved ... to the firm’s thought pieces, blog posts, and conference ... to showcase our insights, capabilities, and to provide timely ... Executive Officer, Cyrus Chowdhury. “An enhanced online presence ...
(Date:7/10/2014)... Best Drug Rehabilitation , which ... close by during a stay in rehab can ... the process is successful, has launched an inspiring ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories section ... Best Drug Rehabilitation graduates who wanted to help ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
(Date:7/10/2014)... new study from Colorado School of Public Health shows ... a major problem in the Navajo Nation and among ... Americans is abysmal with more than three times the ... Batliner, DDS, MBA, associate director of the Center for ... Health. "The number one problem is access to care." ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Study finds widespread oral health problems among Navajo 2
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and manufacturer of ... its financial results for the first quarter,ended March ... the first,quarter of 2008, as compared with $5.2 ... in the first quarter 2008 include wound care ...
... DALLAS, May 6 Claimsnet.com inc. (OTC,Bulletin Board: ... healthcare industry, today reported,its results for the first quarter ... the quarter ended March 31, 2008, the Company reported ... for the first quarter,of 2007., Expenses overall, comprised ...
... U.S. college students are smoking tobacco using waterpipes or ... according to a new study led by a Virginia Commonwealth ... prevalence and perceptions related to waterpipe tobacco smokers and are ... Health. The article is also featured in an editorial in ...
... alleviate the plaguing symptoms of allergies ... and asthma, ... allergies or asthma while outdoors, but why deal with irritating,triggers in your home? ... focus on more important things, not on your,symptoms., Try to prevent as ...
... Acquisition of dermal filler product enhances company,s aesthetic ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical company ... ABR Invent and ABR,Development, developers of the dermal ... of ABR Invent and ABR Development,through a definitive ...
... mole develops into melanoma by showing the interaction of ... The Penn State scientists also demonstrate that therapeutic ... effectively treat this deadly form of cancer. , "We ... Akt3 communicate with one another in a mole, ...
Cached Medicine News:Health News:NUCRYST Announces First Quarter 2008 Financial Results 2Health News:NUCRYST Announces First Quarter 2008 Financial Results 3Health News:NUCRYST Announces First Quarter 2008 Financial Results 4Health News:NUCRYST Announces First Quarter 2008 Financial Results 5Health News:NUCRYST Announces First Quarter 2008 Financial Results 6Health News:NUCRYST Announces First Quarter 2008 Financial Results 7Health News:Claimsnet.com Reports First Quarter 2008 Results 2Health News:Claimsnet.com Reports First Quarter 2008 Results 3Health News:Waterpipe smoking on college campuses may contribute to growing public health problem 2Health News:Double Trouble: Fight Allergy and Asthma in Your Home 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 3Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: